Aevi Genomic Medicine Inc. (Nasdaq: GNMX) reported disappointing results from the SAGA trial of AEVI-001 to treat adolescents with mGluR mutation positive ADHD sending the stock price plummeting $3.23 to close at $2.21.
Aevi Genomic Medicine reports disappointing results
March 20, 2017 at 17:19 PM EDT
